Charlotte brings over a decade of experience in cancer therapeutics. She currently serves as the immunology lead for a preclinical vaccine development program and will play a key role in translational science as the company advances toward its first clinical study in 2026.

Charlotte holds a PhD in cancer biology from the Institute of Cancer Research and has contributed to the field of cancer immunology through her postdoctoral research at King’s College London.

Before joining Epitopea, she worked at Achilles Therapeutics, where she focused on the development of T cell therapies.